Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal
By Helena Smolak
Roche will partner with U.S. biotech company Ascidian Therapeutics to develop gene therapies through its RNA exon editing technology--a method that edits exons at the kilobase level, instead of direct DNA modification--to treat neurological diseases.
The Boston-based startup said Tuesday that it would receive $42 million from Roche as an initial payment, in addition to up to $1.8 billion in research, clinical and commercial milestone payments.
Ascidian will conduct discovery and pre-clinical activities with Roche and will provide the Swiss drugmaker its rights to RNA exon editing technology for undisclosed neurological targets, it said.
The deal is complementary to Roche's own gene editing strategy and aims to benefit its neuroscience portfolio over the next five years, Roche said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
June 18, 2024 08:54 ET (12:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations